【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the Top Companion Diagnostic Companies
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Industry Survey
1.5 Who is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Companion Diagnostics
2.1 Changing Paradigms of Treatment
2.2 What is Personalised Medicine?
2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine
2.3.1 What are In Vitro Diagnostic (IVD) Tests?
2.3.2 How IVDs Help Provide Personalised Treatment
2.4 Companion Diagnostics: Tools for Personalised Medicine
2.4.1 Theranostics: A Subset of Companion Diagnostics
2.5 Biomarkers to Companion Diagnostics
2.5.1 Advancements in Biomarker Discovery
2.5.2 Genomics
2.5.3 Pharmacogenomics
2.5.4 Genomic Biomarkers in Oncology
2.5.5 Proteomics
2.5.6 Metabolomics
2.6 Development of Companion Diagnostics
2.7 Regulations in the Companion Diagnostics Market
2.7.1 FDA’s Draft Guidance on Companion Diagnostics
2.7.1.1 Laboratory Developed Tests (LDT) – A New Direction
3. The World Companion Diagnostics Market, 2016-2026
3.1 The Global Companion Diagnostics Market, 2015
3.2 The Global Companion Diagnostics Market Sales Forecast, 2016-2026
3.3 Companion Diagnostics: Increasing Market Share of the IVD Market
3.4 The Companion Diagnostics Market by Submarket, 2015
3.5 Theranostics: Fastest Growing Segment of the CDx Market
3.6 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2016-2026
3.7 Drivers
3.7.1 Stakeholders in the Companion Diagnostics Market
3.7.2 Regulatory Authorities
3.7.3 Payers
3.7.4 Partnerships
3.8 Restraints
3.8.1 Competitive Landscape
3.8.2 Testing Laboratories
3.8.3 Physicians and Patients
4. Leading US-Based Companion Diagnostic Companies, 2016
4.1 Abbott Laboratories, Inc.
4.1.1 Abbott Laboratories: Financial Overview
4.1.2 Companion Diagnostics Product Portfolio
4.1.2.1 Vysis ALK Break Apart FISH Probe Kit
4.1.2.2 PathVysion HER-2 DNA Probe Kit
4.1.3 Companion Diagnostics in Pipeline
4.1.4 Recent Activity and Collaborations
4.1.4.1 Collaboration with Merck
4.1.4.2 Collaborative Efforts with Idera
4.1.4.3 Collaboration with AstraZeneca
4.2 Myriad Genetics
4.2.1 Myriad Genetics: Financial Overview
4.2.2 Myriad Genetics: Companion Diagnostics Product Portfolio
4.2.2.1 myRisk Hereditary Cancer Test
4.2.2.2 BRACAnalysis®
4.2.2.3 CCP Assay
4.2.2.4 PREZEON™
4.2.3 Myriad Genetics: Companion Diagnostics Pipeline
4.2.3.1 HRD Assay
4.2.4 Myriad Genetics: Companion Diagnostics Collaborations:
4.2.4.1 Myriad/AstraZeneca: Premarket Approval Application
4.2.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
4.2.4.3 Myriad/ TESARO Companion Collaboration
4.2.4.4 Collaboration with AbbVie
4.2.4.5 Agilent/Bristol-Myers Squibb
4.3 Genomic Health
4.3.1 Genomic Health: Financial Overview
4.3.2 Genomic Health: Companion Diagnostics Product Portfolio
4.3.2.1 Oncotype Dx Portfolio
4.3.2.2 Oncotype SEQ
4.3.3 Genomic Health: Companion Diagnostics in Pipeline
4.3.3.1 RxPonder Trial
4.3.4 Genomic Health: Collaborations & Partnerships
4.3.4.1 Partnership with OncoMed
4.3.4.2 Genomic Health Partners with Epic Sciences
4.4 Thermo Fisher Scientific – Life Technologies
4.4.1 Thermo Fisher: Financial Overview
4.4.2 Thermo Fisher: Geographic Segmentation
4.4.3 Recent Collaborations and Acquisitions
4.4.3.1 Acquisition of Life Technologies
4.4.3.2 Acquisition of Prionics
4.4.3.3 Acquisition of Advanced Scientifics, Inc.
4.4.3.4 Acquisition of Alfa Aesar
4.4.3.5 Affymetrix: Thermo Fisher’s Next Target
4.4.3.6 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
4.4.3.7 Thermo Fisher: Life Technologies Collaborates with Merck Serono
4.4.3.8 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC
4.5 Johnson & Johnson
4.5.1 Johnson & Johnson: Financial Overview
4.5.2 Johnson & Johnson Division by Region
4.5.3 Johnson & Johnson: Companion Diagnostics Portfolio
4.5.3.1 Companion Diagnostics Center of Excellence
4.5.4 Johnson & Johnson: Companion Diagnostics Partnerships
4.5.4.1 Collaboration with Tianjin Medical University Cancer Institute and Hospital
4.5.4.2 Partnership with Massachusetts General Hospital
4.5.4.3 Partnership with Biocartis
4.6 Laboratory Corporation of America (LabCorp)
4.6.1 LabCorp: Financial Overview
4.6.2 LabCorp Companion Diagnostics Portfolio
4.6.3 Recent M&A Activity and Other Key Developments
4.6.3.1 Agreement with Medco Health Sciences
4.6.3.2 Non-Exclusive License Agreement with Merck
4.6.3.3 Acquisition of Monogram Biosciences
4.6.3.4 Acquisition of Genzyme Genetics
4.6.3.5 Partnership with ARCA Biopharma
4.7 Illumina
4.7.1 Illumina: Financial Overview
4.7.2 Illumina: Companion Diagnostics Product Portfolio
4.7.2.1 MiSeqDx™ System
4.7.3 Illumina: Recent Activity & Collaborations
4.7.3.1 AstraZeneca Partners with Illumina
4.7.3.2 bioMérieux Collaborates with Illumina
5. Leading European Companion Diagnostic Companies, 2016
5.1 Roche: Global Diagnostics Leader
5.1.1 Ventana Medical Systems (Roche)
5.1.2 Roche: Financial Overview
5.1.3 Roche Diagnostics Geographic Segmentation
5.1.4 Roche’s Collaborations and Recent Activity
5.1.5 Roche Diagnostics: Companion Diagnostics Product Portfolio & Pipeline
5.1.6 Ventana Companion Diagnostics: Robust New Prototype Assays
5.1.7 Recent Companion Diagnostic External Collaborations
5.1.7.1 Foundation Medicine and Roche Collaborate
5.1.7.2 Ventana Partners with Genmab
5.1.7.3 Ferring Collaborates with Roche for CDx Development for Infertility Treatment
5.1.7.4 MedImmune Partners with Ventana
5.1.7.5 Merck Enters Agreement with Ventana
5.1.7.6 AstraZeneca and Roche Partnership
5.1.7.7 Boehringer Ingelheim Collaborate with Roche
5.1.7.8 ImmunoGen Enter Agreement with Ventana
5.1.8 Roche Diagnostics: Major M&A Activity and Strategic Partnerships
5.1.8.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
5.1.8.2 IQuum Acquisition Allows Movement into POC MDx Market
5.1.8.3 Seragon Acquisition Strengthens Leading Position in Oncology
5.1.8.4 Santaris Acquisition Enhances Roche’s Position in RNA-Targeted Drugs Market
5.1.8.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
5.1.8.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
5.1.8.7 Ariosa Acquisition Adds NIPT to Diagnostic Portfolio
5.1.8.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
5.1.8.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
5.1.8.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader
5.2 Qiagen
5.2.1 Qiagen: Financial Overview
5.2.2 Qiagen: Geographic Segmentation
5.2.2.1 Qiagen: Companion Diagnostics Collaborations
5.2.2.2 Collaboration with Eli Lilly
5.2.2.3 Collaboration with AstraZeneca
5.2.2.4 Collaboration with Astellas Pharma
5.2.2.5 Collaboration with Novartis
5.2.2.6 Collaboration with Array BioPharma
5.2.2.7 Collaboration with Protagen
5.3 Agilent Technologies (Dako)
5.3.1 Life Sciences and Diagnostics Business
5.3.2 Agilent Life Sciences and Diagnostics: Financial Overview
5.3.3 Agilent: Next Generation Sequencing Platforms
5.3.4 Recent Companion Diagnostic Collaborations
5.3.4.1 Merck and Aglient Cancer Collaborations
5.3.4.2 Pfizer and Aglient an Ongoing Collaboration
5.3.4.3 Bristol-Myers Squibb and Aglient Partnership
5.4 bioMérieux
5.4.1 bioMérieux: Financial Overview
5.4.2 Sales by Region, 2014
5.4.3 Sales by Technology, 2015
5.4.4 Companion Diagnostics: Recent M&A Activity & Collaboration
5.4.4.1 Collaboration with Gilead Sciences
5.4.4.2 Collaboration with Ipsen
5.4.4.3 Collaboration with Merck
5.4.4.4 Collaborations with GSK and Novartis
5.4.4.5 Mergers, Acquisitions and Collaborations
5.4.5 bioTheranostics: Subsidiary for Oncology Diagnostics
5.5 Siemens Healthcare
5.5.1 Siemens: Financial Overview
5.5.2 Siemens Healthcare
5.5.3 Siemens Diagnostics
5.5.4 Outperforming the Market
5.5.5 Companion Diagnostics
5.5.5.1 Partnership with Pfizer
5.5.5.2 Partnership with ViiV Healthcare
5.5.5.3 Partnership with Tocagen
5.6 MDxHealth
5.6.1 MDxHealth: Financial Overview
5.6.2 Companion Diagnostics
5.6.2.1 PharmacoMDx
5.6.2.2 PredictMDx for Brain Cancer
5.6.2.3 PredictMDx for Colon Cancer
5.6.3 R&D Capabilities
5.6.4 Recent Collaborations and Partnerships
5.6.4.1 Cerba HealthCare Belgium Collaboration
5.6.4.2 SouthGenetics Partnership
5.6.4.3 Sumitomo Sign Pharmaco Partnership for Japan
5.6.4.4 Partnership with GSK
6. Leading Rest of the World Companion Diagnostic Companies, 2016
6.1 MedGenome
6.1.1 MedGenome: Companion Diagnostics Product Portfolio
6.1.1.1 Integrated Genomics Platform
6.1.1.2 OncoPept
6.1.1.3 OncoMD
6.1.1.4 Next-Generation Sequencing Informatics
6.2 Diagnocure
6.2.1 Diagnocure Products
6.2.1.1 Gene Expression and Copy Number Variation (CNV) Analysis
6.2.1.2 Mutation Detection
6.2.1.3 SNP Genotyping
6.2.1.4 Platform and Laboratory Environment
6.2.2 DiagnoCure Collaborations and Partnerships
6.3 Seegene Inc.
6.3.1 Seegene: Product Portfolio
6.3.1.1 MuDT™(Multiple Detection Temperatures) Technology
6.3.1.2 TOCE™ Technology
6.3.1.3 DPO™ Technology
6.3.1.4 READ Technology
6.3.1.5 ACP™ Technology
6.3.2 Seegene Collaborations and Partnerships
6.4 Savyon Diagnostics
6.4.1 Savyon: Product Portfolio
6.4.1.1 NanoCHIP®
6.4.2 Savyon Diagnostics Product Lines
6.4.3 Savyon Diagnostics Services
6.5 Other Leading Companion Diagnostics Partnerships
7. Research Interview
7.1 Dr Ramprasad, Chief Operating Officer, and Mr Hiranjith G H, Director, Corporate Planning, MedGenome
7.1.1 MedGenome Overview
7.1.2 CDx Portfolio at MedGenome
7.1.3 MedGenome’s Competitive Advantage
7.1.4 Future Directions For MedGenome and the Industry
8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026
8.1 SWOT Analysis of the Companion Diagnostics Market, 2016-2026
8.1.1 Strengths
8.1.1.1 A CDx Strategy Decreases the Length of Approval Process
8.1.1.2 Premium Prices for Companion Diagnostics
8.1.1.3 A CDx Development Strategy Can Generate More Effective Drugs
8.1.1.4 Therapeutics Tied with CDx can have Safer Profiles
8.1.1.5 Reducing the Cost of Healthcare
8.1.1.6 Increased Regulatory Scrutiny on Marketed Drugs
8.1.1.7 Targeted Therapies Will Drive the CDx Market
8.1.2 Weaknesses
8.1.2.1 Reimbursement Challenges
8.1.2.2 Lack of Clear Regulatory Guidelines
8.1.2.3 Capital Intensity is High
8.1.3 Opportunities
8.1.3.1 Fast-growing Emerging Markets
8.1.3.2 Next Generation Sequencing
8.1.3.3 Many New CDx/ Pharma Company Partnerships
8.1.4 Threats
8.1.4.1 Complex Business Models and Business Partnerships
8.1.4.2 Medical Device Excise Tax
8.2 STEP Analysis of the Companion Diagnostics Market, 2016-2026
8.2.1 Social Factor: Raising Awareness will Lead to Greater Product Adoption
8.2.2 Technologically Innovation Driven – Growing Manufacturing Efficiency
8.2.3 Economic Potential: Emerging Markets Create Demand
8.2.4 Political Issues: Government Influence
9. Conclusions from Our Research and Analysis
9.1 Overview
9.2 Theranostics: A Fast Growing Market
9.3 Leading Companion Diagnostic Companies
9.4 Pharmaceutical/Diagnostic Partnership Model
9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
9.6 Commercial Drivers of the Companion Diagnostics Market
9.7 Commercial Restraints of the Companion Diagnostics Market
9.8 Concluding Remarks
【レポート販売概要】
■ タイトル：医療機器リーダーシリーズ：コンパニオン診断薬（CDx）開発、製造および販売のトップ企業2016■ 英文：Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016
■ 発行日：2016年8月
■ 調査会社：visiongain
■ 商品コード：VGAIN60907
■ 調査対象地域：グローバル
- ソーシャル及び検知システムにおけるビックデータ収集：市場機会と課題2013-2019（Capturing Big Data in Social and Detection Systems: Market Opportunities and Challenges 2013 -2019）Every large corporation collects and maintains a huge amount of data associated with its customers including their preferences, purchases, habits, travels, and other personal information. In addition to the large volume, much of this data is unstructured, making it hard to manage. This so called “Big Data” is a challenge for industry verticals yet also an opportunity. The enormous growth potential …
- アプリケーション制御におけるベンダー比較分析2016Application control is a security practice to restrict unauthorized and unwanted applications from executing on endpoints to guard the organization‘s endpoint environment. Application control solution protect corporate endpoints such as desktops, laptops, smartphones, tablets, servers, Point-of-Sale (POS) systems, virtual machines, and other fixed functioning devices. These solutions safeguard the …
- 電磁両立性（EMC）シールドの世界市場：導電性塗料、PCBシールド、ガスケット、EMIフィルタ、積層体/テープAbout EMC shielding EMC is the ability of an electrical equipment to perform efficiently in an electromagnetic environment without being affected or influenced by other devices in its proximity. EMC shielding is a protection provided to electrical and electronic devices to protect them from EMI. EMI refers to the phenomenon where electromagnetic radiation affects the performance of electrical and …
- バイオ医療用金属材料の世界市場：ステンレス鋼、チタン合金、コバルト合金、マグネシウムAbout Biomedical Metal Biomedical metals are being used for a number of applications in the Medical sector. The metals commonly used are stainless steel, titanium-based alloys, cobalt-based alloys, nitinol, magnesium and related metals. Stainless steel is the most widely used metal because of its biocompatibility and cost-effectiveness. Biomedical metal find a wide range of applications in implant …
- 世界の有機飼料市場：種類別（シリアル＆穀物、油糧種子）、フォーム別（ペレット、クランブル、マッシュ）、家畜別（家禽、反すう動物、豚、水生動物）、添加物別（アミノ酸、酵素、ビタミン、ミネラル、植物性生物）、地域別“The organic feed market is projected to grow at a CAGR of 6.8%, in terms of value.” The global organic feed market size is estimated at USD 6.8 billion in 2019 and is projected to reach USD 10.1 billion by 2025, recording a CAGR of 6.8% during the forecast period. In Europe, countries such as Germany and France are projected to witness high growth prospects in the years to come, as they are one o …
- 世界のクラウドシステム管理ソフトウェア市場動向（2014-2018）About Cloud System Management Software Cloud management is a term that covers the software and technologies designed to facilitate efficient operations and delivery of applications and computing services to enterprises and other end-users. Many software solutions are being developed for efficient monitoring and management of computing resources. These software solutions also enable monitoring of e …
- Noble Energy, Inc.社の石油・ガス開発・生産動向及びコスト分析（2013年第4四半期）Noble Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2013 Summary Noble Energy, Inc. (Noble Energy) is a US-based independent oil and gas exploration and production company. The company’s exploration and production portfolio are diversified between short-term projects, long-term projects, domestic projects and international projects. Noble Energy’s core operat …
- 半導体マイクロ部品の世界市場2017-2021：マイクロプロセッサ、マイクロコントローラ、DSPAbout Semiconductor Micro Components Semiconductor micro components are an important part of all the electronic devices. Their adoption is directly proportional to the number of electronic devices being sold. The increased popularity of IoT has led to the need of powerful electronics, which in turn has led to the demand for powerful processors. Local processing capability is most often provided by …
- 麻酔ビデオ喉頭鏡の世界市場2016-2020About the Anesthesia Video Laryngoscope Market Anesthesia video laryngoscopes allow physicians to visualize the larynx indirectly through video technology. Laryngoscopy using these devices involves their insertion transnasally or transorally. The video feed from these devices is displayed on a monitor for clinicians to view, helping in the detection of medical abnormalities. The video feed or imag …
- 坑井仕上げ装置の世界市場（～2019）This report estimates the completion equipment & services market value in terms of $million. This has been broken down into component regions and further split into countries. The completion equipment & services are required for the completion of oil and gas well after drilling for the production to commence. The ever-increasing exploration and production activities across the globe and new areas …
- 食品乳化剤の世界市場：モノグリセリド、ジグリセリド、レシチン、ソルビタンエステル、ステアロイルラクチラート、ポリグリセロールエステルThe food emulsifiers market is directly influenced by the growing processed food industry. The rise in the consumption of bakery, confectionery, convenience food market, and dairy, and meat products in developing economies is driving the market for food emulsifiers. Busy work schedules together with health and wellness consciousness among consumers have boosted sales of food emulsifiers as they he …
- 生体活性創傷ケアの世界市場：アルギン酸ドレッシング材、抗菌性ドレッシング材、ハイドロコロイドドレッシング材、成長因子、代用皮膚About the Bioactive Wound Care Market Bioactive wound care products play a critical role in the wound healing process and are derived from the artificial or natural sources. These products are formed by combining different polymers such as collagen, alginates, and silicon. In the past, different natural and synthetic dressings such as cotton wool, bandages, lint, and gauzes with varying degrees of …
- 木質燃料の世界市場2019-2023About this market The The regulations for GHG emissions and the use of bioenergy in heating systems will trigger the wood fuels market growth during the forecast period. The US EPA has been developing common-sense regulatory initiatives for reducing emissions and improving efficiency in emission reduction. In addition, the US EPA has also been supporting the use of CHP due to its cost-effective re …
- ロシアのエネルギー政策及びエネルギー政治：Analyzing Russia’s Energy Policy & Energy PoliticsRussia’s real gross domestic product (GDP) surpassed average growth rates in all other G8 countries in recent years, marking the country’s seventh consecutive year of economic expansion. Russia’s economic growth over the past seven years has been driven primarily by energy exports, given the increase in Russian oil production and relatively high world oil prices during the period. Internally, Russ …
- モーターボート用バッテリーの世界市場2017-2021ABSTRACTAbout Marine Powerboats Batteries A powerboat is a marine vessel powered by an engine. Marine powerboat batteries are used for engine ignition and for powering the electrical components of the boat like boat lights, marine fuse blocks, and electrical panels. The market mainly includes two types of batteries such as lead-acid batteries and lithium-ion batteries. Marine batteries form one of …
